<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Authenticating Your Cell Lines – Why, When and How!

Are you confident that your cell lines and biological models are really what you think they are? Do you know that common PCR-based cell line authentication services may not be able to detect contamination of up to 20% of your cell line?

In this post, we highlight the value of using next-generation sequencing (NGS) as a higher sensitive, accurate and throughput, and multifunctional approach for cell line authentication and contamination detection that has been shown to outperform conventional PCR-based STR assays.

Why Does Cell Line Authentication Matter?

Misidentification and contamination of biological models—including cell lines, organoids, and homograft and xenograft models—remains a challenge. Studies indicate that up to 33% of popular cell lines are contaminated by intra-/interspecies cells, mycoplasma, and/or viruses, and the International Cell Line Authentication Committee (ICLAC) currently lists 530+ misidentified cell lines (as of June 2021) that have no known authentic stock.

The use of misidentified cell lines continues to be a big problem, with Horbach & Halffman (2017) reporting that more than 32,500 papers referred to data from cell lines the ICLAC had classified as misidentified.

Contamination also continues to be pervasive, and it can arise from a variety of sources including cross-contamination with other cell lines and microorganisms (e.g., mycoplasma and/or viruses).

Reproducibility is one of the hallmarks of the scientific method and using misidentified and/or contaminated cell lines can lead to unreliable data (Fig.1). Thus, skipping the authentication step can result in inaccurate conclusions, retraction of publications, and wasted time and money if the cross-contamination or misidentification is found to invalidate the data.

The financial cost of invalid research caused by misidentified cell lines has been estimated to exceed $50 billion. It is therefore not surprising that certain funding agencies such as the NIH and more publishers are requiring researchers to provide biosample authentication.

The U.S. FDA also requires that all materials included in an investigational new drug (IND) application are validated.

Fig 1. Scenarios of data generation using cell lines as tumor models (The EMBO Journal (2022)41:e111307)

Here are the major reasons why researchers should consider authenticating their biosamples:

  • When a new biosample is acquired or developed
  • As a standard quality-control measure
  • When in doubt

Conventional Multiplex PCR-based STR Assays for Cell Line Authentication and Their Limitations

PCR-based STR assays use primers designed to recognize repeated DNA segments of 2-6 base pairs in length. Since the targeted segments vary within a given population, a DNA ‘fingerprint’ can be generated. This technology has been extremely valuable for authenticating cell lines and tracking the identity of human tumors samples that are either derived from patient xenografts or cell lines.

Depending on the vendor, STR assays generally target only 9 to 24 loci, and limitations with PCR technology also restricts the sensitivity and accuracy of the cell line authentication. The accuracy of an STR assay can be especially low in cases where there is a close genetic relationship, such as when trying to authenticate mouse cell lines derived from specific strains of inbred animals that lack unique genetic markers or different tumor cell lineages from the same human donor.

Additionally, cell lines with mutations in mismatch repair (MMR) genes are known to exhibit microsatellite instability and a hypermutator phenotype. Consequently, this can lead to genetic drift and/or outgrowth of contaminating cells and STR misclassification.

The sensitivity of PCR-based cell line authentication assays are claimed to be in the range of 5-10%, though this is variable and depends on a variety of factors including the nature of the cell lines being tested and the quality of the data, however, in reality, sometimes the PCR-based CLA assays can not pick up contaminations up to 20%.

Cell Line Authentication with Deep Sequencing

Significant technological advances have resulted in substantial reductions in the cost of genome sequencing. This includes NGS-based technologies which are amenable to high throughput and multifunctional analyses, including for authenticating large biobanks of cell lines which are notorious for harboring lines that are cross-contaminated.

It is now well-established that NGS significantly outperforms traditional profiling methods for characterizing mouse and human samples, including cell lines, organoids, xenografts, and patient tissues.

At Crown Bioscience, we use deep next-generation sequencing (NGS) with a panel that encompasses 600+ SNPs and chromosome segments to accurately characterize mouse and human samples, at 3000x coverage.

In addition, by using advanced bioinformatics and statistical modeling to support NGS-based cell line authentication, both the identify and frequency of the SNPs can be obtained. And since hundreds of samples can be profiled in a single run, this represents a major improvement over conventional STR assays, which are low throughput.

In terms of coverage, high throughput capability, and sensitivity, NGS is superior to the PCR-based STR assays for cell line authentication which only targets 9 to 24 loci.

Another advantage of NGS lies in its multifunctional capabilities that are not possible with PCR-based STR assays. For instance, this NGS method can also be used to:

  • Detect viruses and mycoplasma.
  • Determine human gender, and other human genetic elements.
  • Trace genetic drift and reconstruct sample phylogenies.
  • Determining the contamination ratio of mixed samples.

We have generated a SNP fingerprint library for the most commonly used oncology research models, which cover more than 1,200 human cancer and 30 mouse cell lines.

The following table compares the deep sequencing and PCR-based STR assays for cell line authentication:

Conclusion

Cell line authentication is increasing in importance funding and regulatory agencies, journals, and the scientific community are requiring researchers to demonstrate the authenticity of their biological samples.

NGS-based SNP profiling is a high throughput, multifunctional, and cost-effective method for cell line authentication. Our unique NGS-based biosample authentication panel encompasses over 600+ SNPs and other chromosome segments that can accurately characterize mouse and human samples including cell lines, organoids, xenograft models, and patient tissues. We have also generated unique DNA fingerprints for the most commonly used oncology research models, covering over 1,200 human cancer and 30 syngeneic cell lines.

If you are interested in learning more about how to use NGS-based profiling for your biosample authentication needs, please visit our Cell Line Authentication page, or contact us by email now.

 

 


Related Posts